MPP Signs Multiple Regional Agreements to Expand Access to Flu Antiviral Medicine
The Medicines Patent Pool (MPP) has signed sublicense agreements with 11 manufacturers across multiple regions to expand access to generic baloxavir marboxil, a single-dose antiviral treatment for influenza that was originally developed by Swiss pharmaceutical company Roche. The announcement, made the night before last Friday’s UN High-Level Meeting on Pandemic Prevention, Preparedness and…
We haven't written up this one. Health Policy Watch has the full story — the link below goes straight to it.
